Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes Export

@article{citeulike:6042136, abstract = {The purpose of this study was to assess the effect of rosiglitazone on bioavailable, free and total testosterone levels in hypogonadal men with type 2 diabetes. Sixteen type 2 diabetic men with hypogonadism were studied before and after administration of rosiglitazone (8 mg/day) for six months, with assessments performed every two months on two consecutive days. We measured testosterone and sex hormone binding globulin (SHBG), visceral adiposity, high-sensitivity CRP (hs-CRP), lipids, microalbuminuria and blood pressure. There was a significant increase in free (p=0.01), bioavailable (p=0.007) and total testosterone (p=0.002), as well as SHBG (p=0.03) levels, with rosiglitazone treatment. Waist circumference and waist/hip ratio decreased with the improvement in insulin sensitivity and glycaemic control (p=0.01). There was also a significant reduction in hs-CRP (p=0.02) and urinary albumin excretion. No significant effect on blood pressure or the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (LDL to HDL) was seen. In conclusion, the insulin-sensitiser rosiglitazone increases bioavailable, free and total testosterone and SHBG levels in hypogonadal men with type 2 diabetes. 10.3132/dvdr.2008.022}, author = {Kapoor, Dheeraj and Channer, Kevin S. and Jones, T. Hugh}, citeulike-article-id = {6042136}, citeulike-linkout-0 = {http://dx.doi.org/10.3132/dvdr.2008.022}, citeulike-linkout-1 = {http://dvr.sagepub.com/content/5/2/135.abstract}, citeulike-linkout-2 = {http://dvr.sagepub.com/content/5/2/135.full.pdf}, citeulike-linkout-3 = {http://view.ncbi.nlm.nih.gov/pubmed/18537102}, citeulike-linkout-4 = {http://www.hubmed.org/display.cgi?uids=18537102}, day = {1}, doi = {10.3132/dvdr.2008.022}, journal = {Diab Vasc Dis Res}, keywords = {diabetes, rosiglitazone, testosterone}, month = {June}, number = {2}, pages = {135--137}, posted-at = {2009-10-30 10:53:09}, priority = {2}, title = {Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes}, url = {http://dx.doi.org/10.3132/dvdr.2008.022}, volume = {5}, year = {2008} }

TY - JOUR ID - citeulike:6042136 L3 - citeulike-article-id:6042136 N2 - The purpose of this study was to assess the effect of rosiglitazone on bioavailable, free and total testosterone levels in hypogonadal men with type 2 diabetes. Sixteen type 2 diabetic men with hypogonadism were studied before and after administration of rosiglitazone (8 mg/day) for six months, with assessments performed every two months on two consecutive days. We measured testosterone and sex hormone binding globulin (SHBG), visceral adiposity, high-sensitivity CRP (hs-CRP), lipids, microalbuminuria and blood pressure. There was a significant increase in free (p=0.01), bioavailable (p=0.007) and total testosterone (p=0.002), as well as SHBG (p=0.03) levels, with rosiglitazone treatment. Waist circumference and waist/hip ratio decreased with the improvement in insulin sensitivity and glycaemic control (p=0.01). There was also a significant reduction in hs-CRP (p=0.02) and urinary albumin excretion. No significant effect on blood pressure or the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (LDL to HDL) was seen. In conclusion, the insulin-sensitiser rosiglitazone increases bioavailable, free and total testosterone and SHBG levels in hypogonadal men with type 2 diabetes. 10.3132/dvdr.2008.022 IS - 2 JF - Diab Vasc Dis Res EP - 137 TI - Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes VL - 5 SP - 135 KW - diabetes KW - rosiglitazone KW - testosterone AU - Kapoor, Dheeraj AU - Channer, Kevin AU - Jones, Hugh PY - 2008/06/01/ UR - http://dx.doi.org/10.3132/dvdr.2008.022 ER -